The joint pain injections market is expected to grow from $2,146.0 million in 2017 to $4,888.5 million by 2026, exhibiting exceptional growth at a compound annual growth rate (CAGR) of 9.7% from 2018 to 2026. As per the latest research cited and brought forward by the Global Burden of Disease Study, the burden associated with musculoskeletal disorders is approximately 6.8% of DALYs worldwide.
Excellent lubrication and shock-absorbing properties similar to synovial fluid have led to an increasing demand for hyaluronic acid injections for joint pain.
In the injections segment of the joint pain injections market, hyaluronic acid injections reign supreme. The human joints are similar to gears subjected to constant wear and tear, and hyaluronic acid possesses excellent lubrication and shock-absorbing properties similar to synovial fluid, thereby reducing joint stiffness and tenderness. Corticosteroid injections are used as an adjuvant medication in joint pain owing to their anti-inflammatory properties and ability to provide short-term relief in joint sprains experienced by athletes and industrial workers.
A significant rise in tenosynovitis and prolonged physical activity drive the knee and ankle joint market's growth.
The joint segment of the joint pain injections market is currently dominated by knee and ankle joints. The major factors associated with its market growth are a significant rise in tenosynovitis and prolonged physical activity. Increasing competition among athletes and rampant growth in the production and manufacturing segments further bolster the knee and ankle joint market's growth. Shoulder and elbow joints are anticipated to register impressive growth in the near future owing to the increasing utilization of electronic gadgets such as laptops, personal computers, and mobile phones among the general population. The rising prevalence of rotator cuff injuries further consolidates the shoulder and elbow joint market's growth.
In North America, market growth is being driven by rising obesity rates and widespread acceptance of viscosupplementation.
North America, with a share of 34%, is leading the regional segment of the joint pain injections market. The chief attributes responsible for its dominance are the rising prevalence of obesity and the high acceptance of viscosupplementation. The domicile of key players such as Sanofi S.A., Allergan Plc., Pfizer Inc., etc., provide the necessary impetus for the joint pain injections market's growth in the North American region. Europe is in the second position with a share of 28%, owing to the rising prevalence of osteoarthritis in the geriatric population. Affordable reimbursement scenarios associated with joint pain injections propel market growth in the European region. Asia Pacific holds a 20% market share and will grow at a faster pace during the forecast period on account of a significant rise in musculoskeletal disorders and increasing cases of accidents and physical trauma.
Periods of History and Forecast
This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
The market is divided into three sections: injection, joint, and geography.
Pharmaceutical companies pioneering in the joint pain injections market are Allergan, Plc., Anika Therapeutics, Inc., Bioventus LLC, Chugai Pharmaceutical Co., Ltd., Flexion Therapeutics, Inc., Ferring B.V., Pfizer, Inc., Sanofi S.A., SEIKAGAKU Corporation, and Zimmer Biomet Holdings, Inc.
Key questions are answered in this report.
Which pharmaceutical companies are manufacturing joint pain injections?
What are the latest market trends prevalent in the market for joint pain injections?
What are the different causes associated with joint pain?
What is the market performance of shoulder and elbow joints going to be?
What is the importance of hyaluronic acid in attenuating the excruciating pain associated with joint osteoarthritis?
Which parameters account for the dominance of North America?
Frequently Asked Questions:
The market for Joint Pain Injections Market is expected to reach US$ 4,888.5 Mn by 2026.
The Joint Pain Injections Market is expected to see significant CAGR growth over the coming years, at 9.7%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.
Anika Therapeutics, Inc., Bioventus LLC, Chugai Pharmaceutical Co., Ltd., Flexion Therapeutics, Inc., Ferring B.V., Pfizer, Inc., Sanofi S.A., SEIKAGAKU Corporation are some of the major players in the global market.
